Author

Timothy J Perren

Consultant Medical Oncologist, Leeds teaching Hospitals NHS Trust - Cited by 15,451 - Clinical trials in breast cancer and gynaecological cancer

Biography

Professor Timothy Perren is a leading consultant medical oncologist specialising in the non-surgical treatment of breast and gynaecological cancers using chemotherapy, hormonal therapy and the latest molecular therapies. Working with the same multidisciplinary team as he does in his NHS role, he provides private cancer treatment at Spire Leeds Hospital and at Nova Healthcare. Profile
Title
Cited by
Year
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...The lancet oncology 18 (12), 1688-1700, 2017201
571
2017
Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial
P Schmid, J Abraham, S Chan, D Wheatley, AM Brunt, G Nemsadze, ...Journal of Clinical Oncology 38 (5), 423-433, 2020202
233
2020
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials
I Vergote, C Coens, M Nankivell, GB Kristensen, MKB Parmar, T Ehlen, ...The Lancet Oncology 19 (12), 1680-1687, 2018201
209
2018
30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study
M Wallington, EB Saxon, M Bomb, R Smittenaar, M Wickenden, S McPhail, ...The Lancet Oncology 17 (9), 1203-1216, 2016201
160
2016
Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes
S Kommoss, B Winterhoff, AL Oberg, GE Konecny, C Wang, SM Riska, ...Clinical Cancer Research 23 (14), 3794-3801, 2017201
103
2017
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ...Annals of Oncology 30 (5), 766-773, 2019201
89
2019
AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled …
P Schmid, J Abraham, S Chan, D Wheatley, M Brunt, G Nemsadze, ...J Clin Oncol 36 (15_suppl), 1007, 2018201
77
2018
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a …
M Gore, A Hackshaw, WE Brady, RT Penson, R Zaino, WG McCluggage, ...Gynecologic oncology 153 (3), 541-548, 2019201
59
2019
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian …
AG Martín, AM Oza, AC Embleton, J Pfisterer, JA Ledermann, ...Gynecologic Oncology 152 (1), 53-60, 2019201
49
2019
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ...Annals of oncology 33 (12), 1250-1268, 2022202
43
2022
The calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy
SJ Storr, S Zhang, T Perren, M Lansdown, H Fatayer, N Sharma, ...Oncotarget 7 (30), 47927, 2016201
29
2016
High EMSY expression defines a BRCA‐like subgroup of high‐grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum
RL Hollis, M Churchman, CO Michie, T Rye, L Knight, A McCavigan, ...Cancer 125 (16), 2772-2781, 2019201
28
2019
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a …
D Miles, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ...Annals of Oncology 32 (10), 1245-1255, 2021202
26
2021
Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.
JA Ledermann, AC Embleton, T Perren, GC Jayson, GJS Rustin, SB Kaye, ...Journal of Clinical Oncology 35 (15_suppl), 5506-5506, 2017201
25
2017
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised …
SP Blagden, AD Cook, C Poole, L Howells, IA McNeish, A Dean, JW Kim, ...The Lancet Oncology 21 (7), 969-977, 2020202
24
2020
A functional form for a representative individual arterial input function measured from a population using high temporal resolution DCE MRI
L Georgiou, DJ Wilson, N Sharma, TJ Perren, DL BuckleyMagnetic Resonance in Medicine 81 (3), 1955-1963, 191
20
2019
The clinical impact of using complex molecular profiling strategies in routine oncology practice
JF Laes, P Aftimos, P Barthelemy, J Bellmunt, G Berchem, C Camps, ...Oncotarget 9 (29), 20282, 2018201
19
2018
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis
KA Gelmon, PA Fasching, FJ Couch, J Balmaña, S Delaloge, ...European Journal of Cancer 152, 68-77, 2021202
18
2021
Bevacizumab for newly diagnosed ovarian cancers: Best candidates among high-risk disease patients (ICON-7)
O Colomban, M Tod, J Peron, TJ Perren, A Leary, AD Cook, C Sajous, ...JNCI Cancer Spectrum 4 (3), pkaa026, 2020202
17
2020
Serial MRI scans help in assessing early response to neoadjuvant chemotherapy and tailoring breast cancer treatment
H Fatayer, N Sharma, D Manuel, B Kim, A Keding, T Perren, G Velikova, ...European Journal of Surgical Oncology (EJSO) 42 (7), 965-972, 202
16
2016

Referred From: https://scholar.google.com/citations?user=IW4tWfMAAAAJ&hl=en

Cited by
Citations 15451
h-index 59
i10-index 127
Open Access Journals